Introduction Ischaemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide and poses an ...

As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

CHOICE-2 supports intra-arterial alteplase after successful reperfusion ...

Results from the CHOICE-2 trial show a 15% absolute increase in excellent functional outcomes with intra-arterial alteplase ...

A large US registry-based study shows that longer door-in-door-out (DIDO) times at the referring hospital are strongly ...

Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...

The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

Delivering intra-arterial alteplase after successful mechanical thrombectomy improved functional recovery in patients with ...

Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) ...

Safety-net definitional ambiguity undermines targeted funding, limiting the ability to sustain staffing, infrastructure, and quality improvement needed for optimal stroke care across diverse ...

One Step GPS has been recognized with Capterra's 2025 "Best Ease of Use" in both the GPS Tracking and Fleet Management categories. With over 20,000 fleets relying on its technology, One Step GPS is ...